These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28137644)

  • 1. Measuring the effectiveness and impact of an open innovation platform.
    Carroll GP; Srivastava S; Volini AS; Piñeiro-Núñez MM; Vetman T
    Drug Discov Today; 2017 May; 22(5):776-785. PubMed ID: 28137644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open innovation in early drug discovery: roadmaps and roadblocks.
    Reichman M; Simpson PB
    Drug Discov Today; 2016 May; 21(5):779-88. PubMed ID: 26743597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open innovation: A paradigm shift in pharma R&D?
    Schuhmacher A; Gassmann O; Bieniok D; Hinder M; Hartl D
    Drug Discov Today; 2022 Sep; 27(9):2395-2405. PubMed ID: 35643258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
    Schuhmacher A; Gassmann O; McCracken N; Hinder M
    J Transl Med; 2018 May; 16(1):119. PubMed ID: 29739427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector.
    Martinez-Grau MA; Alvim-Gaston M
    Pharmaceut Med; 2019 Jun; 33(3):193-198. PubMed ID: 31933287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A measure of productivity and innovation in the pharmaceutical industry 2011-2015.
    Harrison R
    Drugs Today (Barc); 2016 Nov; 52(11):627-633. PubMed ID: 28112281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Open Innovation Drug Discovery (OIDD): a potential path to novel therapeutic chemical space.
    Alvim-Gaston M; Grese T; Mahoui A; Palkowitz AD; Pineiro-Nunez M; Watson I
    Curr Top Med Chem; 2014; 14(3):294-303. PubMed ID: 24283973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing access and innovation: India's Supreme Court rules on imatinib.
    Rajkumar R; Kesselheim AS
    JAMA; 2013 Jul; 310(3):263-4. PubMed ID: 23824051
    [No Abstract]   [Full Text] [Related]  

  • 9. Open innovation platforms to boost pharmaceutical collaborations: evaluating external compounds for desired biological activity.
    Nilsson N; Felding J
    Future Med Chem; 2015; 7(14):1853-9. PubMed ID: 26393392
    [No Abstract]   [Full Text] [Related]  

  • 10. The successes and challenges of open-source biopharmaceutical innovation.
    Allarakhia M
    Expert Opin Drug Discov; 2014 May; 9(5):459-65. PubMed ID: 24702304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of open innovation in drug discovery: an industry perspective.
    Rees S
    Future Med Chem; 2015; 7(14):1835-8. PubMed ID: 26420551
    [No Abstract]   [Full Text] [Related]  

  • 12. ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape.
    Greenberg A; Kiddell-Monroe R
    Global Health; 2016 Sep; 12(1):54. PubMed ID: 27627882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accessing external innovation in drug discovery and development.
    Tufféry P
    Expert Opin Drug Discov; 2015 Jun; 10(6):579-89. PubMed ID: 25910932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open Access Could Transform Drug Discovery: A Case Study of JQ1.
    Arshad Z; Smith J; Roberts M; Lee WH; Davies B; Bure K; Hollander GA; Dopson S; Bountra C; Brindley D
    Expert Opin Drug Discov; 2016; 11(3):321-32. PubMed ID: 26791045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Private versus social incentives for pharmaceutical innovation.
    González P; Macho-Stadler I; Pérez-Castrillo D
    J Health Econ; 2016 Dec; 50():286-297. PubMed ID: 26944633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing R&D models in research-based pharmaceutical companies.
    Schuhmacher A; Gassmann O; Hinder M
    J Transl Med; 2016 Apr; 14(1):105. PubMed ID: 27118048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Open innovation for pharmaceutical industries].
    Matsumoto Y; Sakata T
    Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):199-204. PubMed ID: 23575425
    [No Abstract]   [Full Text] [Related]  

  • 20. A new approach to assess drug development performance.
    Rosiello A; Dimitri N; Fiorini F
    Drug Discov Today; 2013 May; 18(9-10):420-7. PubMed ID: 23337387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.